The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC
Information source: Kos Pharmaceuticals
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Intermittent Claudication; Peripheral Vascular Disease
Intervention: Niacin Extended Release and Lovastatin Tablets (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Kos Pharmaceuticals
Summary
The purpose of this study is to compare the dose response and safety of Niacin
ER/Lovastatin, Niaspan® and Lovastatin with each other, in subjects with leg pain caused by
a narrowing of their leg arteries.
At least 870 subjects, with leg pain caused by a narrowing of their leg arteries will take
part in this study.
Both Niaspan and lovastatin (Mevacor®) are approved by the United States Food and Drug
Administration (FDA) to treat high cholesterol. Niacin ER/Lovastatin (Advicor®), a
combination of these two drugs, is also approved by the FDA to treat high cholesterol. The
use of Niacin ER/Lovastatin to treat narrowing of leg arteries and relieve āintermittent
claudicationā (leg pain caused by narrowing of the arteries in the leg) is considered
investigational. An investigational use is one that is not approved by the FDA.
Clinical Details
Official title: The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - a Matrix Design
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Detailed description:
This is a Phase 3, 32-week, double-blind, diet-intervention, randomized, parallel group,
ten-arm, multi-center, multi-national, dose titration study evaluating the safety and
efficacy of NL in patients with intermittent claudication (IC).
The objectives of this study are to evaluate the safety and efficacy of NL in patients with
IC. The primary efficacy analysis will be the percent change from baseline in Peak Walking
Time (PWT) calculated from the natural logarithm of the ratio of the time walked on
treadmill at the Week 32 Visit divided by the time walked at baseline. Other efficacy
measures will include Claudication Onset Time (COT) percent changes from baseline to Week
32 , changes in Ankle Brachial Index (ABI), Quality of Life (QoL) percent changes at Weeks
20 and 32, lower limb amputations, composite of cardiovascular events (MI, stroke, and
vascular death), and coronary and peripheral artery revascularizations. Safety variables
will include serum transaminases, routine chemistry parameters, hematology, and adverse
events. Pharmacokinetic analyses will be conducted as well.
Eligibility
Minimum age: 40 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
INCLUSION CRITERIA:
- Men & women at least 40 years of age or older. Women must not be pregnant nor
breast-feeding & not planning to become pregnant or to breast-feed.
- History of IC of the lower extremities which has been present for at least 6 months
with no change in symptoms in the previous 3 months prior to screening.
- LDL-C of <160 mg/dL and Triglycerides <800.
EXCLUSION CRITERIA:
- Severe neuropathy.
- Gross obesity (BMI ā„ 40).
- Presence of critical limb ischemia defined as ischemic rest pain, gangrene,
ulceration, or pending amputation of a lower extremity due to severe PAD.
- Surgical intervention to alleviate symptoms of claudication within 6 months or
endovascular interventions within 3 months.
- Documented CAD taking any cholesterol-modifying agent and unable to undergo washout
as judged by the Investigator or due to personal choice.
- Systolic blood pressure ā„160 mmHg &/or diastolic blood pressure ā„95 mmHg.
- Presence of clinically significant laboratory test abnormalities for liver or renal
function tests, thyroid function or HgbA1C.
- History of alcohol abuse or currently drinks alcohol in excess.
Locations and Contacts
Tatum Ridge Internal Medicine, Phoenix, Arizona 85032, United States
Scottsdale Cardiovascular Research Institute, LLC, Scottsdale, Arizona 85251, United States
VA Palo Alto Health Care System, Palo Alto, California 94304, United States
Sacramento Heart & Vascular Medical Associates, Sacramento, California 95825, United States
University of California-Davis; Department of Surgery, Sacramento, California 95819, United States
Clinical Research Center of California, San Diego, California 92103, United States
North County Internal Medicine, Vista, California 92083, United States
University of Colorado Health Sciences Center, Denver, Colorado 80200, United States
University of Connecticut Health Center, Farmington, Connecticut 06030, United States
Cardiovascular Center of Sarasota, Sarasota, Florida 34239, United States
Clinical Research Center of Georgia, Warner Robins, Georgia 31093, United States
River Cities Cardiology, MPC, Jeffersonville, Indiana 47130, United States
HPV Heart P.A., Columbia, Maryland 21044, United States
St. Joseph Mercy-Oakland Research Office, Pontiac, Michigan 48341, United States
Saint Louis University, Saint Louis, Missouri 63104, United States
Carolina Pharmaceutical Research, Statesville, North Carolina 28625, United States
COR Clinical Research, Oklahoma City, Oklahoma 73104, United States
New Hope Research of Oregon, Portland, Oregon 97219, United States
Penn State College of Medicine, Hershey, Pennsylvania 17033, United States
Radiant Research, Philadelphia, Pennsylvania 19115, United States
Mainline Health Heart Center, Wynnewood, Pennsylvania 19096, United States
Clinical Cardiology Research Center, Dallas, Texas 75246, United States
Baylor College of Medicine, Houston, Texas 77030, United States
Pro Research Group, LLC, San Antonio, Texas 78205, United States
Hampton Roads Center for Clinical Research, Inc., Norfolk, Virginia 23502, United States
Care Foundation, Inc, Wausau, Wisconsin 54401, United States
Additional Information
Starting date: October 2003
Last updated: October 31, 2006
|
